Home > Share Market > Stocks > Bafna pharmaceuticals > Financial Statements > BAFNAPH Key Financial Ratios

Bafna pharmaceuticals Financial Statements

BAFNAPH Ratio Analysis

  • Tabular Data
  • Graph
  • Consolidated
  • Standalone
Y/e 31 Mar Mar-2020 Mar-2019 Mar-2018 Mar-2017
Growth matrix (%)        
Revenue growth (2) (8.10) (27) (24)
Op profit growth (109) (62) 505 (1,225)
EBIT growth (89) 108 (13) 276
Net profit growth 31 12.80 (14) 38.70
Profitability ratios (%)        
OPM 2.88 (31) (74) (8.90)
EBIT margin (4.20) (37) (16) (14)
Net profit margin (58) (44) (35) (30)
RoCE (2.80) (20) (7.20) (6.60)
RoNW (18) (17) (10) (9.70)
RoA (9.90) (5.90) (3.90) (3.60)
Per share ratios ()        
EPS -- -- -- --
Dividend per share -- -- -- --
Cash EPS (118) (9.40) (8.80) (13)
Book value per share 216 8.06 16 22.90
Valuation ratios        
P/E -- -- -- --
P/CEPS (0.10) (1.20) (3.20) (2.30)
P/B 0.04 1.36 1.75 1.29
EV/EBIDTA (2.30) (5.50) (29) (29)
Payout (%)        
Dividend payout -- -- -- --
Tax payout -- 5.84 14.90 (4.40)
Liquidity ratios        
Debtor days 133 207 302 342
Inventory days 88.90 84 106 93
Creditor days (231) (219) (116) (159)
Leverage ratios        
Interest coverage 18.70 7.60 1.12 0.77
Net debt / equity (0.10) 2.28 1.15 1.87
Net debt / op. profit (4.50) (3.30) (1.20) (14)
Cost breakup ()        
Material costs (47) (64) (81) (80)
Employee costs (24) (21) (16) (10)
Other costs (26) (46) (77) (19)

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000